Trial Profile
A Phase II Clinical Trial of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 13 Apr 2020 Planned End Date changed from 1 Dec 2019 to 1 Mar 2021.
- 13 Apr 2020 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2020.
- 31 May 2019 Preliminary results (n=22) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).